VEGF Gene MRNA Expression in Patients with Coronary Artery Disease

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2012 Jun 20

PMID 22711306

Citations 13

Authors

Mahsa M Amoli

Parvin Amiri

Amin Alborzi

Bagher Larijani

Sadaf Saba

Javad Tavakkoly-Bazzaz

Affiliations

Soon will be listed here.

Abstract

To assess the expression of vascular endothelium growth factor (VEGF) mRNA in unstimulated peripheral blood mononuclear cells of patients with and without coronary artery disease (CAD). We also studied whether the functional VEGF -2,578C/A polymorphism may influence the level of VEGF mRNA expression in individuals undergoing coronary angiography because chest pain. We assessed 50 consecutive patients with angiographically confirmed CAD (CAD+). Also, 50 consecutive individuals with normal coronary studies were included in the study for comparison. VEGF mRNA expression was examined using quantitative real-time PCR and genotyping for VEGF -2,578C/A was performed using ARMS-PCR technique. VEGF mRNA expression was significantly decreased in CAD+ patients when compared to CAD- individuals (p = 0.01). The frequency of VEGF -2578 allele C and genotype CC was increased in CAD+ patients. In this regard, homozygosity for the CC genotype was more commonly observed in CAD+ (30 %) than in those without CAD disease (18 %). However, the difference was slightly out of the range of significance (p = 0.1). In addition, a trend for reduction in the expression of VEGF mRNA was observed when patients carrying the VEGF -2,578AA genotype were compared with those VEGF -2,578AC heterozygous or those homozygous for the VEGF -2,578CC genotype. VEGF gene expression is decreased in individuals with CAD+ disease. The VEGF -2,578C/A polymorphism may influences the expression of VEGF.

Citing Articles

A simplified in vitro disease-mimicking culture system can determine the angiogenic effect of medicines on vascular diseases.

Moon S, Ito Y Cytotechnology. 2025; 77(2):75.

PMID: 40062227 PMC: 11889311. DOI: 10.1007/s10616-025-00736-4.

Genetic research in Immunogenetics Group of Endocrinology and Metabolism Research Institute.

Asgarbeik S, Amoli M, Vahidi A, Klashami Z J Diabetes Metab Disord. 2024; 23(2):1553-1561.

PMID: 39610527 PMC: 11599698. DOI: 10.1007/s40200-021-00753-y.

VEGF Polymorphisms (, and ) and Cardiovascular Implications in Long COVID Patients.

Cozma A, Sitar-Taut A, Orasan O, Briciu V, Leucuta D, Sporis N Int J Mol Sci. 2024; 25(16).

PMID: 39201353 PMC: 11354396. DOI: 10.3390/ijms25168667.

Genetic polymorphisms in VEGFA and VEGFR2 genes associated with coronary heart disease susceptibility and severity.

Hajer F, Hana S, Saoussen C, Abdelhak F, Nadia B, Ameni D Mol Biol Rep. 2023; 50(12):10169-10177.

PMID: 37924452 DOI: 10.1007/s11033-023-08899-z.

Study of the Association between Polymorphisms and the Risk of Coronary Artery Disease in Koreans.

Ko E, Kim I, Lee J, Park H, Park H, Kim S J Pers Med. 2022; 12(5).

PMID: 35629182 PMC: 9144104. DOI: 10.3390/jpm12050761.

References

Stehouwer C, Lambert J, Donker A, van Hinsbergh V . Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997; 34(1):55-68. DOI: 10.1016/s0008-6363(96)00272-6. View

Petrovic D . The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease. Cardiovasc Hematol Agents Med Chem. 2010; 8(1):47-54. DOI: 10.2174/187152510790796183. View

Rhee E, Oh K, Lee W, Kim S, Jung C, Kim B . The differential effects of age on the association of KLOTHO gene polymorphisms with coronary artery disease. Metabolism. 2006; 55(10):1344-51. DOI: 10.1016/j.metabol.2006.05.020. View

Lin T, Wang C, Su H, Hsu P, Juo S, Voon W . Functional vascular endothelial growth factor gene polymorphisms and diabetes: effect on coronary collaterals in patients with significant coronary artery disease. Clin Chim Acta. 2010; 411(21-22):1688-93. DOI: 10.1016/j.cca.2010.07.002. View

Senger D, Connolly D, Van de Water L, Feder J, Dvorak H . Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990; 50(6):1774-8. View

Henry T, Annex B, McKendall G, Azrin M, Lopez J, Giordano F . The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003; 107(10):1359-65. DOI: 10.1161/01.cir.0000061911.47710.8a. View

Biselli P, Guerzoni A, Godoy M, Pavarino-Bertelli E, Goloni-Bertollo E . Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population. Heart Vessels. 2008; 23(6):371-5. DOI: 10.1007/s00380-008-1057-6. View

Ferrara N . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25(4):581-611. DOI: 10.1210/er.2003-0027. View

Marsh S, Nakhoul F, Skorecki K, Rubin A, Miller B, Leibu R . Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care. 2000; 23(9):1375-80. DOI: 10.2337/diacare.23.9.1375. View

10.

Genuth S, Alberti K, Bennett P, Buse J, DeFronzo R, Kahn R . Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11):3160-7. DOI: 10.2337/diacare.26.11.3160. View

11.

Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y . Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008; 247(1):21-6. DOI: 10.1007/s00417-008-0915-3. View

12.

Dvorak H, Brown L, Detmar M, Dvorak A . Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146(5):1029-39. PMC: 1869291. View

13.

Bayer I, Caniggia I, Adamson S, Langille B . Experimental angiogenesis of arterial vasa vasorum. Cell Tissue Res. 2002; 307(3):303-13. DOI: 10.1007/s00441-002-0512-4. View

14.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

15.

Tavakkoly-Bazzaz J, Amoli M, Pravica V, Chandrasecaran R, Boulton A, Larijani B . VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep. 2010; 37(7):3625-30. DOI: 10.1007/s11033-010-0013-6. View

16.

Unemori E, Ferrara N, Bauer E, Amento E . Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol. 1992; 153(3):557-62. DOI: 10.1002/jcp.1041530317. View

17.

Amoli M, Hasani-Ranjbar S, Roohipour N, Sayahpour F, Amiri P, Zahedi P . VEGF gene polymorphism association with diabetic foot ulcer. Diabetes Res Clin Pract. 2011; 93(2):215-219. DOI: 10.1016/j.diabres.2011.04.016. View

18.

Sfar S, Saad H, Mosbah F, Chouchane L . Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness. Mol Biol Rep. 2007; 36(1):37-45. DOI: 10.1007/s11033-007-9149-4. View

19.

Feldman E, Stevens M, Thomas P, Brown M, Canal N, Greene D . A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994; 17(11):1281-9. DOI: 10.2337/diacare.17.11.1281. View

20.

Hendel R, Henry T, Rocha-Singh K, Isner J, Kereiakes D, Giordano F . Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation. 2000; 101(2):118-21. DOI: 10.1161/01.cir.101.2.118. View